The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot-blinded randomized feasibility trial comparing an investigational hand therapy intervention (IHT) to a traditional occupational therapy (TOT) intervention to prevent chemotherapy induced peripheral neuropathy (CIPN) of the hands in patients (pts) receiving chemotherapy (CTX).
 
Gayle S. Jameson
Honoraria - Celgene
Speakers' Bureau - Celgene
 
Cynthia Cooper
No Relationships to Disclose
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Bayer; Biogen (I); Fujifilm; Genzyme (I); Merrimack; Novartis (I); Teva (I)
Speakers' Bureau - Biogen (I); Celgene; Genzyme (I); Merrimack; Novartis (I); Taiho Pharmaceutical; Teva (I)
 
Lynne Hull
No Relationships to Disclose
 
Lana Caldwell
No Relationships to Disclose
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Cell Therapeutics; CerRx; EmergingMed; McKesson; Medtronic; SynDevRx
Honoraria - Celgene; Cerulean Pharma; Genentech
Consulting or Advisory Role - AADi; Alethia Biotherapeutics; Alpha Cancer Technologies; Aptose Biosciences; Arsia Therapeutics; Arvinas; Bellicum Pharmaceuticals; BiolineRx; Biological Dynamics; Bionomics; Bristol-Myers Squibb; CanBas; Cavion; Cerulean Pharma; CV6 Therapeutics ; CytomX Therapeutics; CytRx Corporation; dalian wanchun biotechnology; Deciphera; DNAtrix; EMD Serono; Esperance Pharmaceuticals; Evelo Therapeutics; Five Prime Therapeutics; Formula Pharmaceuticals; Fujifilm; Gilead Sciences; HealthCare Pharmaceuticals; Histogen; Horizon Discovery; Horizon Pharma; Idera; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Inform Genomics; Innate Pharma; Insys Therapeutics; Intezyne Technologies; Kalos Therapeutics; Kinex; Kura Oncology; Lantern Pharma; Lilly; Lixte Biotechnology; MBC Pharma; Medelis; Medical Prognosis Institute; Merus; miRNA Therapeutics; Nucana; Oncolytics; Oncolyze; Pain Therapeutics; Pain Therapeutics; Pfizer; Pharmacyclics; Pharmamab; Phosplatin Therapeutics; Progen; RenovoRx; Samsung; Samumed; Senhwa Biosciences; SOTIO; Strategia Therapeutics; Sun Biopharma; Superlab Far East; Synergene; Systems Imagination; TD2; Theravance; Tolero Pharmaceuticals; Toray Industries; Trovagene; Ventana Medical Systems
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Aduro Biotech (Inst); Agios (Inst); ArQule (Inst); Baxalta (Inst); Biomarin (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); miRNA Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Strategia (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
Travel, Accommodations, Expenses - FORMA Therapeutics; Merrimack